Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?
We all know the narrative by now: One by one, Big Pharma execs are migrating to biotech in search of a higher level of focus, more direct impact, nimbler operating structure and equity. But is that anecdotal, or a quantifiable trend? What else is notable about this new generation of biotech execs?
Helping sketch that picture, Coulter Partners, a life sciences executive recruitment firm based in London, sifted through 50 of its recent biotech CEO appointments between Europe and the US and offered a glance of the collective profile of this group.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters